An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

After Novo Nordisk and Eli Lilly transformed the market for obesity treatment, a flood of drugmakers has jumped in with ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune ...

Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Research into RNA interference, a Nobel Prize-winning technique to mute disease-causing gene mutations, has gained momentum in recent years. Since 2018, six medicines based on the technology have won ...

“As the industry transitions from traditional drug discovery and life sciences R&D to faster-paced, complex modalities, ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

The president-elect has said he’ll let Robert F. Kennedy Jr. “go wild” on healthcare, while many expect a leadership change ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...